Syprine

Product manufactured by Bausch Health Us Llc

Application Nr Approved Date Route Status External Links
NDA019194 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

Indications And Usage Syprine Is Indicated In The Treatment Of Patients With Wilson's Disease Who Are Intolerant Of Penicillamine. Clinical Experience With Syprine Is Limited And Alternate Dosing Regimens Have Not Been Well-Characterized; All Endpoints In Determining An Individual Patient's Dose Have Not Been Well Defined. Syprine And Penicillamine Cannot Be Considered Interchangeable. Syprine Should Be Used When Continued Treatment With Penicillamine Is No Longer Possible Because Of Intolerable Or Life Endangering Side Effects. Unlike Penicillamine, Syprine Is Not Recommended In Cystinuria Or Rheumatoid Arthritis. The Absence Of A Sulfhydryl Moiety Renders It Incapable Of Binding Cystine And, Therefore, It Is Of No Use In Cystinuria. In 15 Patients With Rheumatoid Arthritis, Syprine Was Reported Not To Be Effective In Improving Any Clinical Or Biochemical Parameter After 12 Weeks Of Treatment. Syprine Is Not Indicated For Treatment Of Biliary Cirrhosis.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Trientine Hydrochloride TRIENTINE HYDROCHLORIDE ZINC19364225

Comments